

Hyperglycemic Hyperosmolar Syndrome (HHS) Care Process Model Synopsis

Background

Hyperglycemic Hyperosmolar Syndrome (HHS) is an acute diabetic emergency that exists in a continuum with Diabetic Ketoacidosis (DKA). In general, HHS is associated with type 2 diabetes and thus is relatively rare in pediatrics with most of the literature focused on individual case reports or case series. However, it is notably becoming more common as the prevalence of type 2 diabetes in the pediatric population increases. One series identified HHS in 3.7% of patients with newly diagnosed type 2 diabetes.¹ HHS has been diagnosed in patients with antibody negative diabetes as young as age 5.² However, it has also been reported in patients with type 1 diabetes.³ Approximately 25-30% of cases presenting with combined features of DKA and HHS.⁴ Treatment for HHS is distinct from DKA, though, and there have been reports of poorer outcomes in those managed on a standard DKA protocol.⁵ HHS often has a delayed diagnosis compared to DKA due to the lack of significant abdominal symptoms.^{6,7}

There is minimal guidance in the literature particularly for management of pediatric patients. Here, we provide a summary of case reports and case series with recommendations for management by organ system.

Definitions

The exact definition of HHS varies in the literature. Historically called Hyperglycemic Hyperosmolar Non-Ketotic Coma, obtundation was one of the required features of the disorder. Now it is characterized by significant hyperglycemia (≥ 600 mg/dL) and dehydration with hyperosmolality (typically >320 mOsm/kg), without evidence of ketoacidosis (classically a $\text{CO}_2 >15$ and negative to small urine ketones). Though altered mental status is a common finding in these patients, it is not necessary for significant alterations to be present.

The Osmolality cut-off is the most variable criteria in the literature. Not only does the value vary from 300 mOsm/kg to 350 mOsm/kg,^{5,8} but the technique for determining osmolality also varies. Some authors use measured serum osmolality, some using calculated osmolality, and some use effective osmolality (which removes Urea from consideration of the calculated value, as it moves freely across the cell membrane)⁹.

Based on discussions with Children's Mercy and review of our own cases of DKA and HHS, we classify HHS as a blood glucose ≥ 600 mg/dL and a calculated or measured serum osmolality ≥ 350 mOsm/kg. This cut-off was chosen based on those who seem to have additional complications, such as altered mental status or acute kidney injury. The formula used by our lab to calculate osmolality is: $1.89 \cdot \text{Na} + 1.38 \cdot \text{K} + 1.08 \cdot (\text{Glu} \cdot 0.0555) + 1.03 \cdot \text{BUN} + 7.45$. This formula was derived using analysis of measured osmolality and BMPs obtained in our laboratory and differs from the standard calculations used in online osmolality calculators (which often underestimate the measured osmolality, especially in the setting of DKA).

As the prevalence of mixed DKA/HHS is relatively high at our hospital, based on currently available data, we will not use ketone measurements or serum bicarbonate to exclude patients from the diagnosis of HHS but recognize that management may need to be individualized based on degree of ketoacidosis. Additionally, even those with osmolalities greater than 350 mOsm/kg may not behave classically like

HHS, and some patients with an osmolality between 320 and 350 mOsm/kg may behave more like HHS, particularly in those with serum glucoses >1000 mg/dL or elevated creatinine. Therefore, evaluation of the entire clinical picture is important when evaluating and managing these patients.

Initial ED Management

The goal of the initial management is to recognize HHS early during treatment. If new onset diabetes or DKA/HHS is suspected, initial labs should include a POC glucose and ketones, BMP with osmolality, and lactate level (as elevated lactate can also cause a high anion gap metabolic acidosis⁷). If no previous history of diabetes and POC glucose suggests diagnosis, new onset labs should also be obtained. If febrile, blood cultures, and other infectious workup should be obtained as clinically indicated.

New onset diabetes with hyperosmolality should be suspected in patients who are hypertensive with signs of dehydration,⁹ those with dehydration with continued brisk urine output,⁷ or in those with dehydration and altered mental status.

If POC glucose is greater than 500 mg/dL (or reads 'HI'), the patient should receive an initial fluid bolus of 10-20 mL/kg, instead of the usual 10 mL/kg in the DKA protocol (max 1000 mL). If there is evidence of hemodynamic instability (such as hypotension), this bolus should be administered faster and boluses continued until the patient is normotensive. Additional blood pressure support may be needed to achieve this goal.

Patients with HHS should not receive Lantus (or other long-acting insulins) initially so that the fall in blood glucose levels can be managed more closely.

If initial BMP confirms the diagnosis of HHS and the blood glucose levels remains above 550 mg/dL, hourly plasma/serum glucose checks will need to be performed, along with BMP with Osm every 2 hours to monitor changes in electrolyte concentrations.

Admission to the ICU

PICU admission or transfer should be considered in any patient with:

1. Altered mentation
2. Calculated osmolality >350 mOsm/kg
3. Persistent glucose >550 mg/dL (unable to read on POC glucose monitor)
4. Significant hyperkalemia (>6 mmol/L)
5. Hemodynamic instability (hypotension, significant tachycardia, etc)
6. Bicarbonate level <5 mmol/L or ≤ 10 mmol/L if under 5 years of age
7. Excessive urine output suggesting need for urine output replacement

Fluid Management

The degree of dehydration in patients with HHS is often masked due to hypertonicity. Initially, there is often poor renal perfusion resulting in a low urine output. As renal perfusion improves with fluid therapy, a profound osmotic diuresis occurs as the kidneys work to excrete excess glucose. This diuresis, combined with a decrease in serum osmolality, results in movement of water out of the intravascular spaces (either into the urine or into intracellular spaces during rehydration), resulting in hypovolemic shock.⁸

There are no prospective data to guide management of children and adolescents with HHS. These guidelines are derived from recommendations for management of HHS in adults with the recognition that children may be at a higher or lower risk of complications (cerebral edema, etc.) based on additional factors.

1. Goal of initial fluid therapy is to expand intra- and extra- vascular volume and restore normal renal perfusion.
2. Initial bolus should be 20 ml/kg of isotonic saline. Additional boluses may be necessary to restore perfusion and maintain normal blood pressure.
3. Fluid deficit should be assumed to be 12-15% of body weight and replaced over 24-48 hours
4. Fluids should be adjusted to ensure sodium level declines slowly (0.5 mmol/L/hr)
5. Dextrose should be added to fluids earlier than in DKA, to maintain glucose drop 75-100 mg/dL/hr and stabilize at 250-300 mg/dL until rehydration occurs (i.e. serum sodium level normalizes).
6. Consider replacing urine output 1:1 with ½ NS to reduce ongoing fluid losses. One study suggested starting urine replacement once UOP exceeded 40 mL/m²/hr, which approximates 1.5 ml/kg/hr.⁹

Caution should be used in those with mixed DKA/HHS, as fluid administration in excess of 4 L/m²/day has been associated with the development of cerebral edema.

Cardiovascular Status

As above, there is often a period of refractory hypovolemic shock following initial rehydration. Early initiation of vasopressor support (epinephrine, norepinephrine, dopamine) should be considered. An echocardiogram should be obtained if inotropes are needed.

Electrolyte abnormalities are not uncommon (see Electrolytes section) and can result in arrhythmias. Therefore, cardiac lead monitoring is recommended in any patient with HHS during the initial phases of treatment.

Insulin

Insulin is generally not recommended in the initial management of HHS. Rather, recommendations are to continue aggressive fluid management and start an insulin drip once the drop in blood glucose levels falls below 50 mg/dL/hr.

However, in cases of mixed DKA and HHS, insulin may be needed to stop ketosis. In these cases, starting an insulin drip at 0.02 to 0.05 u/kg/hr may be reasonable, along with titration of the insulin drip and fluid rate to achieve a decline in blood glucose no more than 75-100 mg/dL/hr.⁸ Our endocrinology team then recommends increasing the insulin drip up to the standard 0.1 u/kg/hr once serum osmolality is less than 320 mOsm/kg if necessary for treatment of DKA.

Lantus (or other long-acting insulin analogs) should not be administered until blood glucose levels are <400 mg/dL to reduce the risk of a rapid drop in glucose levels.

Electrolytes

HHS is associated with risk of multiple electrolyte abnormalities, particularly with potassium. Frequent monitoring of potassium and phosphorus (recommendation for BMP every 2-3 hours and phos every 3-4 hours) should be included in management, with replacement as needed.

Hypokalemia is the most worrisome of the electrolyte abnormalities, as these patients tend to have very high potassium losses (more significant than in DKA). There are reports of pediatric patients having cardiac rhythm abnormalities, including ventricular tachycardia,¹⁰ as a result of hypokalemia. Therefore, it is recommended to start replacement of potassium at 40 mEq/L once levels are in the normal range and adequate renal function has been established. Higher rates of potassium may be needed once insulin therapy is initiated.⁸

Hyperkalemia may also be present initially. In these cases, insulin may need to be started sooner to manage potassium levels but should be administered with dextrose to prevent a rapid decline in glucose levels.

Bicarbonate **should not** be administered, as it increases the risk of hypokalemia.

Hypophosphatemia has been associated with HHS.^{11,12} Severe hypophosphatemia may lead to rhabdomyolysis (see Rhabdomyolysis section). Therefore, phosphate should be administered in a 50:50 mixture of potassium phosphate and another potassium salt (such as potassium chloride or potassium acetate) to reduce the risk of severe hypophosphatemia or hypocalcemia from phosphate replacement.⁸

Ionized calcium should also be monitored frequently. In cases of hemodynamic instability calcium acts as an inotrope. The goal should be to maintain ionized calcium in the normal range. In addition, calcium levels can be very low in the oliguric phase of rhabdomyolysis and acute renal injury, requiring frequent replacement. Levels can also be high in the diuretic phase of recovery from acute renal injury.¹³

There is no guidance on whether *magnesium* replacement is beneficial in the treatment of HHS. However, it should be repleted in the setting of hypocalcemia to allow improvement in calcium levels.⁸

Kidney Injury

The significant dehydration that defined HHS results in acute kidney injury. There is often significant elevation in the BUN and Creatinine with initial labs, which often improves with rehydration. However, other features of HHS (especially rhabdomyolysis, detailed in the following section) may result in additional injury after the initial hypoperfusion is corrected. Therefore, consideration for CRRT or hemodialysis, should be ongoing based on the clinical status of the patient, particularly if urine output decreases during treatment.

Rhabdomyolysis

Rhabdomyolysis is a frequently cited complication of HHS and is occasionally seen in DKA.¹⁴ It may be induced by hypophosphatemia.⁵ It has been seen in association with a malignant hyperthermia-like syndrome as well (see Fever/Hyperthermia section).¹⁵

It is recommended to trend Creatine Kinase (CK) levels every 2-3 hours for early detection.⁸ If previously normal, but a rise in creatinine is noted, CK levels should be repeated.

Fever/Hyperthermia

In adults, infection is often a trigger for the development of HHS, and thus fevers are relatively common. However, infection has not been identified as a common cause of HHS in pediatrics.¹ There has been an association of a malignant hyperthermia-like syndrome that occurs with HHS.¹⁵ It has been proposed to be a reaction to a preservative in IV insulin,¹⁶ but not all cases have been associated with insulin initiation.¹⁵

It is recommended that in instances of fever or hyperthermia, an infectious workup should be completed, and any underlying infection treated. If no infectious etiology is found, dantrolene may be considered for treatment of hyperthermia.

Hematology

Thrombosis has been identified as a complication of HHS.¹ This is thought to be due to the dehydration and hemoconcentration that results, though elevated vasopressin levels may also promote clotting tendencies.⁵ Current recommendations are to reserve anticoagulant therapy for those who have central lines or are expected to be immobile for longer than 24-48 hours.⁸

DKA¹⁷⁻¹⁹ and HHS have also been associated with thrombocytopenia-associated multi-organ failure.²⁰ This condition is defined by new onset thrombocytopenia (<100K) or drop of 50% from baseline over less than 30 hours, and overt disseminated intravascular coagulopathy (DIC). If suspected, an LDH level can be drawn and is typically high in this condition. Those with multi-organ dysfunction may benefit from plasma exchange.²¹

Mental Status and Cerebral Edema

It is not uncommon to have altered mental status associated with HHS. In general, mental status improves during treatment. A complication not infrequently seen in DKA is cerebral edema. There have been few reported cases of cerebral edema in the setting of HHS,^{1,11} indicating that the incidence is significantly less than DKA. However, if there is a deterioration of mental status during treatment, this should be promptly investigated and consideration for treatment of cerebral edema should be made.⁸ Of note, less is known about the incidence of cerebral edema in cases of mixed DKA/HHS, so particular care should be taken in this population.

Deteriorating mental status should also raise concern for cerebral thrombosis, as cerebral thromboses have been noted in patients with HHS.^{22,23} Anecdotally, there have been instances of CNS venous thrombosis in patients with severe dehydration secondary to HHS, though this is not widely reported in the literature. In these cases, a head CT should be obtained urgently.

Team Members Involved in Creating this Care Process Model:

Team Leaders: Michelle Knoll, MD and Ryan McDonough, DO, Endocrinology

EBP Team Member: Jacqueline Bartlett, PhD, RN

Team Members:

- Marita Thompson, MD, Critical Care Medicine
- Alyssa Stoner, MS, DO, Critical Care Medicine
- Erica Zarse, MD, Endocrinology Fellow
- Kelsee Halpin, MD, MPH, Endocrinology
- Sonalee Ravi, MD, Endocrinology



Care Process Model Finalized: 7.15.21; 6.25.22

- Cintya Schweisberger, DO, Endocrinology Fellow
- Erica Wee, MD, Endocrinology Fellow

References

1. Fournier SH, Weinzimer SA, Levitt Katz LE. Hyperglycemic hyperosmolar non-ketotic syndrome in children with type 2 diabetes*. *Pediatr Diabetes*. 2005;6(3):129-135. doi:10.1111/j.1399-543X.2005.00113.x
2. Al Hassani N, Kaplan W. Hyperglycaemic hyperosmolar syndrome in a 5-year-old girl with newly diagnosed type 2 diabetes mellitus. *Diabetes Metab*. 2019;45(5):488-489. doi:10.1016/j.diabet.2017.11.004
3. Hernández Moreno A, Sanz Fernández M, Ballesteros Pomar MD, Rodríguez Sánchez A. Hiperglycemic hyperosmolar state: An unusual way of first appearance of type 1 diabetes in children. *Endocrinol Nutr Organo Soc Espanola Endocrinol Nutr*. 2016;63(5):252-253. doi:10.1016/j.endonu.2016.02.001
4. Pasquel FJ, Tsegka K, Wang H, et al. Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study. *Diabetes Care*. 2020;43(2):349-357. doi:10.2337/dc19-1168
5. Nambam B, Menefee E, Gungor N, Mcvie R. Severe complications after initial management of hyperglycemic hyperosmolar syndrome and diabetic ketoacidosis with a standard diabetic ketoacidosis protocol. *J Pediatr Endocrinol Metab*. 2017;30(11):1141-1145. doi:10.1515/jpem-2017-0183
6. Price A, Losek J, Jackson B. Hyperglycaemic hyperosmolar syndrome in children: Patient characteristics, diagnostic delays and associated complications. *J Paediatr Child Health*. 2016;52(1):80-84. doi:10.1111/jpc.12980
7. Venkatraman R, Singhi SC. Hyperglycemic hyperosmolar nonketotic syndrome. *Indian J Pediatr*. 2006;73(1):55-60. doi:10.1007/BF02758261
8. Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. *Pediatr Diabetes*. 2018;19(S27):155-177. doi:10.1111/pedi.12701
9. Bhowmick SK, Levens KL, Rettig KR. Hyperosmolar hyperglycemic crisis: an acute life-threatening event in children and adolescents with type 2 diabetes mellitus. *Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol*. 2005;11(1):23-29. doi:10.4158/EP.11.1.23
10. Sorcher JL, Badaki-Makun O, Ngo TL. Unresponsive: A Case of Hyperglycemia and Altered Mental Status. *Clin Pediatr Emerg Med*. 2019;20(4):100726. doi:10.1016/j.cpem.2019.100726
11. Morales AE, Rosenbloom AL. Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes. *J Pediatr*. 2004;144(2):270-273. doi:10.1016/j.jpeds.2003.10.061
12. Zubkiewicz-Kucharska A, Chrzanowska J, Noczyńska A. Hyperosmolar hyperglycaemic state (HHS) as the first manifestation of type 2 diabetes in a child. *Pediatr Endocrinol Diabetes Metab*. 2019;25(2):85-89. doi:10.5114/pedm.2019.85819

13. AKMAL M, BISHOP JE, TELFER N, NORMAN AW, MASSRY SG. Hypocalcemia and Hypercalcemia in Patients with Rhabdomyolysis with and without Acute Renal Failure*. *J Clin Endocrinol Metab.* 1986;63(1):137-142. doi:10.1210/jcem-63-1-137
14. Mercer S, Hanks L, Ashraf A. Rhabdomyolysis in Pediatric Patients With Diabetic Ketoacidosis or Hyperglycemic Hyperosmolar State. *Glob Pediatr Health.* 2016;3. doi:10.1177/2333794X16671391
15. Hollander AS, Olney RC, Blackett PR, Marshall BA. Fatal malignant hyperthermia-like syndrome with rhabdomyolysis complicating the presentation of diabetes mellitus in adolescent males. *Pediatrics.* 2003;111(6 Pt 1):1447-1452. doi:10.1542/peds.111.6.1447
16. Wappler F, Roewer N, Köchling A, Braune H, Reissinger T, Schulte am Esch J. Fulminant malignant hyperthermia associated with ketoacidotic diabetic coma. *Intensive Care Med.* 1996;22(8):809-812. doi:10.1007/BF01709525
17. Alsaied T, Goldstein SL, Kaddourah A, Poynter SE. Thrombocytopenia-associated multi-organ failure caused by diabetic ketoacidosis. *Pediatr Int.* 2016;58(3):232-234. doi:https://doi.org/10.1111/ped.12780
18. Patra KP, Scott LK. Diabetic Ketoacidosis Preceding Thrombocytopenia Associated Multiple Organ Failure in a Child. *JOP J Pancreas.* 2011;12(1):40-43. doi:10.6092/1590-8577/3382
19. Khan MR, Maheshwari PK, Haque A. Thrombotic microangiopathic syndrome: A novel complication of diabetic ketoacidosis. *Indian Pediatr.* 2013;50(7):697-699. doi:10.1007/s13312-013-0175-0
20. Tufan-Pekkucuksen N, Gazzaneo MC, Afonso NS, Swartz SJ, Angelo JR, Srivaths P. Thrombocytopenia-associated multi-organ failure secondary to hyperglycemic, hyperosmolar non-ketotic syndrome: A case report. *Pediatr Diabetes.* 2018;19(3):574-577. doi:10.1111/pedi.12608
21. Fortenberry JD, Nguyen T, Grunwell JR, et al. Therapeutic Plasma Exchange in Children With Thrombocytopenia-Associated Multiple Organ Failure: The Thrombocytopenia-Associated Multiple Organ Failure Network Prospective Experience. *Crit Care Med.* 2019;47(3):e173-e181. doi:10.1097/CCM.0000000000003559
22. Nwosu BU, Adhami S, Rogol AD. Stroke in a child with Adams-Oliver syndrome and mixed diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. *J Pediatr Endocrinol Metab JPEM.* 2012;25(3-4):357-361. doi:10.1515/jpem-2011-0465
23. Misra UK, Kalita J, Bhoi SK, Dubey D. Spectrum of hyperosmolar hyperglycaemic state in neurology practice. *Indian J Med Res.* 2017;146(Suppl 2):S1-S7. doi:10.4103/ijmr.IJMR_57_15